Identification of microRNA profiles in docetaxel-resistant human non-small cell lung carcinoma cells (SPC-A1)

Docetaxel has been used as first‐line chemotherapy in advanced non‐small cell lung carcinoma (NSCLC), but further extensive and effective application is prevented by drug resistance. MicroRNAs (miRNAs) have recently been identified as important posttranscriptional regulators, which are involved in various biological processes. The aim of this study was to identify microRNA expression profiles involved in the development of docetaxel resistance in NSCLC. Here, microarray chip technology was employed to identify miRNA expression profiles in docetaxel‐resistant human NSCLC cell line (SPC‐A1/docetaxel). Then, the changes of miRNAs expression (>2‐fold compared with control SPC‐A1 cell line) were testified by quantitative real‐time RT‐PCR (qRT‐PCR) assay. Furthermore, the potential target genes regulated by selected miRNAs were analysed by various target prediction tools. The expression of a total of 52 miRNAs showed significant difference between SPC‐A1/docetaxel cells and control SPC‐A1 cells (P < 0.01). Six miRNAs (miR‐192, 200b, 194, 424, 98 and 212) exhibited more than 2‐fold changes in their expression levels, which were validated by qRT‐PCR. The expression of three miRNAs (miR‐200b, 194 and 212) was significantly down‐regulated in SPC‐A1/docetaxel cells, while the expression of other three miRNAs (miR‐192, 424 and 98) was significantly up‐regulated in SPC‐A1/docetaxel cells (P < 0.01). Potential target genes controlled by six selected miRNAs were divided into four groups according to various functions: apoptosis and proliferation (71 genes), cell cycle (68 genes), DNA damage (26 genes) and DNA repair (59 genes). The expression of a few target genes in SPC‐A1/docetaxel and SPC‐A1 cells were further confirmed by qRT‐PCR and Western blot. Taken together, the identification of microRNA expression profiles in docetaxel‐resistant NSCLC cells could provide a better understanding of mechanisms involved in drug sensitivity or resistance, which would be helpful to develop novel strategies for targeted therapies in chemorefractive NSCLC patients.

[1]  M. Chamberlain,et al.  Cross-talk between signalling pathways and the multidrug resistant protein MDR-1 , 2001, British Journal of Cancer.

[2]  J. Ji,et al.  Chemoresponse to docetaxel correlates with expression of the survivin splicing variants in patients with gastric cancer. , 2007, Hepato-gastroenterology.

[3]  N. Hanna,et al.  Chemotherapy and Radiotherapy in the Treatment of Resectable Non–Small-Cell Lung Cancer , 2006, Annals of Surgical Oncology.

[4]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[5]  D. Gandara,et al.  Promising new agents in the treatment of non-small cell lung cancer , 2009, Cancer Chemotherapy and Pharmacology.

[6]  C. Croce,et al.  MicroRNAs in Cancer. , 2009, Annual review of medicine.

[7]  D. Belostotsky,et al.  MicroRNAs and messenger RNA turnover. , 2006, Methods in molecular biology.

[8]  R. Weinberg,et al.  MicroRNAs in malignant progression , 2008, Cell cycle.

[9]  J. Tisaire,et al.  Cost-minimisation analysis of three regimens of chemotherapy (docetaxel-cisplatin, paclitaxel-cisplatin, paclitaxel-carboplatin) for advanced non-small-cell lung cancer. , 2002, Lung cancer.

[10]  P. Hernández,et al.  Erlotinib as a single agent in select subsets of patients with advanced non-small-cell lung cancer. , 2007, Clinical lung cancer.

[11]  S. Horwitz.  Taxol (paclitaxel): mechanisms of action. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  W. Hait,et al.  Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer. , 2002, Cancer research.

[13]  B. Harfe,et al.  MicroRNAs in Development , 2006, TheScientificWorldJournal.

[14]  Barbara McGrogan,et al.  Taxanes, microtubules and chemoresistant breast cancer. , 2008, Biochimica et biophysica acta.

[15]  D. Beer,et al.  MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. , 2009, Cancer research.

[16]  J. Bertino,et al.  Role of Pemetrexed in Non-Small Cell Lung Cancer , 2007, Cancer investigation.

[17]  K. Syrigos,et al.  Developments in the treatment of non-small cell lung cancer. , 2007, Anticancer research.

[18]  C. Belani.  Docetaxel in combination with platinums (cisplatin or carboplatin) in advanced and metastatic non-small cell lung cancer. , 2002, Seminars in Oncology.

[19]  A. Tong.  Small RNAs and non-small cell lung cancer. , 2006, Current molecular medicine.

[20]  N. Hanna,et al.  The role of maintenance chemotherapy in advanced nonsmall cell lung cancer , 2009, Current opinion in oncology.

[21]  A. Venkitaraman,et al.  AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. , 2003, Cancer cell.

[22]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[23]  J. Mendell,et al.  MicroRNAs in cell proliferation, cell death, and tumorigenesis , 2006, British Journal of Cancer.

[24]  Leslie Wilson,et al.  βIII-Tubulin Induces Paclitaxel Resistance in Association with Reduced Effects on Microtubule Dynamic Instability* , 2005, Journal of Biological Chemistry.

[25]  R. Geney,et al.  Overcoming Multidrug Resistance in Taxane Chemotherapy , 2002, Clinical chemistry and laboratory medicine.

[26]  S. Walker.  Updates in non-small cell lung cancer. , 2008, Clinical journal of oncology nursing.

[27]  F. Levy.  Developments in Treatment , 2002 .

[28]  G. Bepler,et al.  Phase II Study of First-Line Sequential Chemotherapy with Gemcitabine-Carboplatin Followed by Docetaxel in Patients with Advanced Non-Small Cell Lung Cancer , 2005, Oncology.

[29]  F. Giles,et al.  Microtubule dynamics as a target in oncology. , 2009, Cancer treatment reviews.